Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive's Stephen Gunnion with an update on the company's pancreatic cancer trials. The company recently announced preliminary results from its ASCEND phase 2 trial at the ASCO Gastrointestinal Conference. According to Mazzo, data from the randomized, double-blind, placebo-controlled Cohort A group demonstrated promising trends in overall survival and efficacy. He highlighted that four complete responses were observed in the Certepetide group out of 63 patients—a stark contrast to zero in the standard care group. This is particularly significant when compared to other trials, such as NAPOLI-3, which had only one complete response in nearly 400 patients. Mazzo also discussed Cohort B, which investigates a double-dose regimen of Certepetide to explore pharmacodynamic improvements and optimize treatment efficacy. In addition, Lisata released preliminary data from its iLSTA trial, which examines combining Certepetide with immunotherapy (Durvalumab) and cytotoxics for pancreatic cancer. Mazzo emphasized increased T-cell tumor penetration and higher partial response rates in early data, suggesting potential for enhanced treatment outcomes. Catch the full interview to learn more about these breakthroughs. Visit Proactive’s YouTube channel for updates, like this video, subscribe, and enable notifications to stay informed. #LisataTherapeutics #PancreaticCancer #ClinicalTrials #ASCENDTrial #Certepetide #CancerResearch #Immunotherapy #PharmaNews #BiotechInnovations #ProactiveInvestors